The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
After experiencing an exceptionally strong performance due to COVID-induced stockpiling and panic buying in the first quarter of last year, the generics industry largely saw revenues drop due to pandemic-related challenges in first quarter of 2021.
The companies that saw unprecedented growth due to the first wave of COVID-19 (see sidebar) failed to match the record-breaking...